Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance frequently occurs in patients with non-small-cell lung cancer (NSCLC). EGFR Thr790Met mutation (T790M+) is seen in ∼50% of patients. We assessed the safety, tolerability, and pharmacokinetics (PK) of BPI-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, P., Zheng, X., Wang, Y., Chu, T., Wang, S., Jiang, J., Qian, J., Han, X., Ding, L., Cui, L., Li, H., Li, L., Chen, X., Han, B., Hu, P., Shi, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271465/
https://www.ncbi.nlm.nih.gov/pubmed/35526510
http://dx.doi.org/10.1016/j.esmoop.2022.100473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271465/
https://www.ncbi.nlm.nih.gov/pubmed/35526510
http://dx.doi.org/10.1016/j.esmoop.2022.100473

Ejemplares similares